ASHP Testifies During Senate Hearing on 340B Drug Pricing Program

Published: March 15, 2018

ASHP reinforced its support for the 340B Drug Pricing Program during March 15 testimony before the Senate Committee on Health, Education, Labor & Pensions. 

Joseph Hill, director of ASHP’s Government Relations Division, emphasized that the program helps maximize scarce federal resources while providing low-income and uninsured patients access to lifesaving medications. Hill’s testimony noted that savings from the 340B program fund critical pharmacist-provided care services such as treatment for opioid abuse, medication management services, and disease management for chronic diseases. Hill also stressed the importance of program compliance and highlighted ASHP’s efforts to ensure that covered entities use the program in a manner consistent with its purpose.

Watch Hill's testimony here.


Joseph Hill 340B


Posted March 15, 2018

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information